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Abstract
Aims/hypothesis This paper presents the relationship between islet autoantibodies, precursors of type 1 diabetes, and the devel-
opment of persistent asthma, allergic rhinitis and atopic eczema.
Methods A total of 2159 newborns who had a first-degree relative with type 1 diabetes and selected HLA genotypes were
followed until the youngest participant reached 10 years of age. Islet cell antibodies (ICA) were detected using indirect immu-
nofluorescence. Autoantibodies to insulin (IAA), GAD (GADA), the tyrosine phosphatase-related insulinoma-associated 2
molecule (IA-2A) and zinc transporter 8 (ZnT8A) were quantified with the use of specific radiobinding assays. As an ancillary
study, the incidence of asthma, allergic rhinitis and eczema was assessed in 1106 of these children using the International Study
of Asthma and Allergies in Childhood (ISAAC) core questionnaire when the children were 9–11 years old. HRs with 95% CIs
were calculated to depict the incidence of these diseases following seroconversion to autoantibody positivity.
Results The cumulative incidence of atopic eczema, allergic rhinitis and persistent asthma were 22%, 9% and 7.5%, respectively,
by 9–11 years of age. The occurrence of diabetes-related autoantibodies showed a protective association with subsequently
reported incidence of asthma and eczema. The incidence of rhinitis was not significantly related to the occurrence of IAA or
GADA (statistical power was limited), but demonstrated the same inverse relationship as did the other diseases with ICA or when
multiple autoantibodies first appeared together.
Conclusions/interpretation The findings add evidence to the relationships between these atopic diseases and diabetes-related
autoimmunity and also suggest that, for eczema, the interaction depends upon which autoantibody appeared first.
Trial registration ClinicalTrials.gov NCT00179777




insulinoma-associated 2 molecule autoantibodies
IAA Insulin autoantibodies
ICA Islet cell antibodies
ISAAC International Study of Asthma and
Allergies in Childhood
TRIGR Trial to Reduce Insulin Dependent Diabetes in the
Genetically at Risk
ZnT8A Zinc transporter 8 antibodies
Introduction
The prevalence rates of asthma and other allergic diseases in
children share many of the same characteristics as that of type
1 diabetes and its associated autoimmunity. Both have been
increasing in prevalence during the last six decades, particu-
larly in industrialised countries, although the increase may
have levelled off in some [1–4].
Allergic diseases are caused by over-reactivity of the
human immune system against foreign proteins, leading to
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asthma, allergic rhinitis, conjunctivitis, atopic eczema and
food allergies. Parental heredity is a strong risk factor for the
development of both asthma and atopic eczema: if one of the
parents has the allergic disease the risk is increased at least
twofold; if both, the increase is three- to fourfold [5, 6].
However, the rapid increase in the occurrence of these
diseases over time indicates that environmental factors
are also crucial in the disease aetiology. The same
picture is found in diabetes-related autoimmunity and
type 1 diabetes. A family history of type 1 diabetes
increases diabetes risk and there is substantial evidence
of the role of environmental exposures [7].
The immune abnormalities that lead to allergic diseases are
initiated in infancy and possibly even during the fetal period.
Diabetes-related autoimmunity has also been shown to occur
in infancy for those presenting with insulin autoantibodies
(IAA) as their first-appearing autoantibody, but at a later age
for those presenting with GAD autoantibodies (GADA) first
[8, 9]. Thus, early months of development may be critical for
the maturation of the immune system as well as complex
immune regulatory networks that result in functional distur-
bances, autoimmunity and allergic disorders.
The nutritional factors identified in epidemiological studies
as possibly affecting the development of islet cell autoimmu-
nity and allergic diseases and asthma include breastfeeding,
age at introduction of new foods in infancy, dietary fatty acids,
dietary antioxidants, vitamin D, foods that affect gut microbi-
ota and obesity [10, 11]. There is contrasting evidence of
whether prolonged feeding with a hydrolysed infant formula
compared with a formula based on intact cow’s milk reduces
infant and childhood allergies or diabetes-related autoimmu-
nity [12–14].
This paper explores the relationship between the incidence
of asthma, rhinitis and eczema and the incidence of diabetes-
related autoantibodies in a subset of the children enrolled in
the Trial to Reduce Insulin Dependent Diabetes in the
Genetically at Risk (TRIGR) study (ClinicalTrials.gov
Identifier: NCT00179777). The TRIGR infant feeding trial
was designed to examine whether weaning to an extensively
hydrolysed infant formula, as compared with formula based
on cow’s milk, delays or prevents the development of islet cell
autoimmunity and/or type 1 diabetes in children at increased
genetic risk of type 1 diabetes. TRIGR was a double-blind,
randomised controlled trial of a dietary intervention (hydro-
lysed vs standard infant formula) that enrolled 2159 newborn
first-degree relatives of patients with type 1 diabetes from 77
clinical sites in 15 countries [15–17]. The intervention period
concluded in August 2007. This cross-sectional asthma and
allergy ancillary study was performed between 2013 and
2016, when the children were 9–11 years old.
Methods
Participants Newborn infants who had a first-degree relative
with type 1 diabetes and defined HLA genotypes were recruit-
ed into TRIGR between May 2002 and January 2007, and
followed until diagnosis of type 1 diabetes or until the youn-
gest participant reached 10 years of age in 2017.
Randomisation of the infants who met the inclusion criteria
took place before birth or immediately after birth. Altogether,
2159 newborn infants (1142 boys [52.9%]) with an eligible
HLA genotype (41.9% of the genotyped infants) were
randomised to the TRIGR intervention study. Randomisation
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resulted in balanced groups with 1081 infants in the casein
hydrolysate group and 1078 in the cow’s milk group. In total,
516 infants (23.9%) carried the high-risk HLA genotype, 953
(44.1%) carried moderate-risk genotypes, 668 (30.9%) carried
mild-risk genotypes and 22 (1.0%) carried the rare mild-risk
genotype (Table 1). The first-degree relative with type 1 diabe-
tes was the mother in 1055 infants (48.9%), the father in 723
(33.5%) and a sibling in 308 (14.3%), whereas 73 participants
(3.4%) had multiple affected relatives. The median follow-up
time for the diagnosis of diabetes was 11.5 years (range
3 months to 14.8 years; mean 11.0 years).
Written, informed consent was obtained from the family
before enrolment into the TRIGR study. The study was
approved by the ethics committees of all participating centres.
Dietary intervention Infants were randomly assigned weaning
to either the intervention or control formula, produced specif-
ically for this study. The intervention formula was an exten-
sively hydrolysed casein-based formula, while the control
formula was composed of 80% intact cow’s milk protein
and 20% hydrolysed milk protein, and formulated so that the
taste and smell would be indistinguishable from the interven-
tion formula. Study formulas were prepared and coded with
the use of four colours by Mead Johnson Nutrition and were
blinded to all investigators except the Data Management Unit
(DMU). Newborn infants requiring supplemental feeding
before randomisation (e.g., infants born at night or on week-
ends) received banked breast milk or Nutramigen, an exten-
sively hydrolysed casein-based formula.
Breastfeeding was practiced at the discretion of the partic-
ipating mothers, and maternal diets were unmodified.
Breastfeeding was encouraged and exceeded national aver-
ages in both groups [18]. The dietary intervention period
lasted until the infant was at least 6 months of age, and if by
that time the child had not received the study formula for at
least 60 days, study formula feeding was continued until
60 days of study formula exposure was reached, but not
beyond 8 months of age. Parents were asked not to feed the
children any commercial or other baby foods containing
bovine protein during the intervention period. Adherence to
the protocol was monitored by means of regular family nutri-
tion interviews (at the ages of 0.5, 1, 2, 3, 4, 5, 6, 7 and
8 months) and by the analysis of cow’s milk antibodies in
serum samples. Detailed study design and methods have been
previously published [16–18]. Online informed consent for
this ancillary study was obtained for all study participants
from a parent or primary caretaker.
HLA genotyping Cord blood or a heel stick blood sample
collected on filter paper shortly after birth was immediately
sent to the Turku (Europe and Australia) or Pittsburgh (North
America) laboratory for HLA genotyping. HLA genotyping
for the selectedDQB1 andDQA1 alleles was performed using
sequence-specific oligonucleotide hybridisation, with quality
control between the two laboratories carefully maintained.
The following genotypes were regarded as eligible: (1) HLA
DQB1*02/DQB1*03:02 [high-risk]; (2) HLA DQB1*03:02/x
(x not DQB1*02, DQB1*03:01 or DQB1*06:02) [moderate
risk]; (3) HLA DQA1*05-DQB1*02/y (y not DQA1*02:01-
DQB1*02, DQB1*03:01, DQB1*06:02 or DQB1*06:03)
[mild risk]; and (4) HLA DQA1*03-DQB1*02/y (y not
DQA1*02:01-DQB1*02, DQB1*03:01, DQB1*06:02 or
DQB1*06:03) [rare mild risk].
Diabetes-related autoantibodies Blood samples for autoanti-
body analyses were obtained (after application of analgesic
cream) at the follow-up visits when the children were 3, 6,
9, 12, 18 and 24 months of age, and annually thereafter up to
the age of 10–14 years. Serum samples were stored at −70°C
until they could be analysed. Islet cell antibodies (ICA) were
detected with the use of indirect immunofluorescence, while
the four biochemical autoantibodies (IAA, GADA, autoanti-
bodies to the tyrosine phosphatase-related insulinoma-associ-
ated 2 molecule [IA-2A] and autoantibodies to zinc transport-
er 8 [ZnT8A]) were quantified with the use of specific
radiobinding assays [19]. Each autoantibody except for
ZnT8A was analysed from all samples available. ZnT8A
was initially quantified from the samples taken at the ages of
2, 3, 4, 6, 8, 10 and 12 years. If the 2 year sample tested
positive, the samples obtained at the ages of 3, 6, 8, 9, 12
and 18 months were also analysed to assess the age at sero-
conversion. Similarly, any later samples between a negative
and a positive sample were analysed.
Study endpoints The incidence of asthma, allergic rhinitis and
eczema was assessed using the standardised and validated
International Study of Asthma and Allergies in Childhood
(ISAAC) core questionnaire on the child’s history presented
online to the parents of the participating children [20]. The
online assessment included additional questions related to
the child’s use of asthma medications (if applicable), whether
the child was ever diagnosed by a physician with certain
diseases and food allergies, exposure to possible allergens
and other factors related to asthma and/or allergies.
Persistent asthma was defined as doctor-diagnosed asthma
plus either any wheezing symptom during the preceding
12 months or use of asthma medication during the preceding
12 months. Age at onset of asthma was determined by the
question: ‘At what age did the symptom of asthma start or at
what age did the child first wheeze?’Wheezing was defined as
any of the following during the past 12months: wheezy sound
in respiration; wheezy sound during respiration in association
with physical activity; difficulties in respiration in the morning
on waking up; or wheezy respiration without having sniffles
or respiratory infection. Allergic rhinitis was defined as
doctor-diagnosed hay fever or allergic rhinoconjunctivitis
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during the preceding 12 months. Age at onset of allergic rhini-
tis was based on the age of the child at the onset of symptoms
including sneezing, nasal congestion or rhinitis other than
with respiratory infections, accompanied by itching of the
eyes and tearing. Atopic eczema was defined as ever having
doctor-diagnosed atopic eczema. Age of onset of atopic ecze-
ma was based on the question: ‘At what age did the child first
have atopic eczema?’ All online questionnaires, including
ISAAC, were available in local languages.
Statistical analyses The cumulative incidence of onset of each
endpoint from birth was estimated using a modified Kaplan–
Meier disease-free survival function. The differences between
groups in the cumulative incidence functions, and the associ-
ated hazard functions, were tested using the logrank test
according to the actual diet consumed. The relative risk of
disease onset between groups was estimated with the Cox
proportional hazards model using time-dependent covariates.
Multivariate analyses included characteristics that were found
to be statistically significantly associated with autoantibody
incidence from the univariate analyses. The autoantibody-
negative group was defined to be the referent population for
comparing disease incidence by first-appearing autoantibody.
When comparing characteristics between the extensively
hydrolysed formula and cow’s milk formula groups, the t test
was applied for normally distributed variables and the non-
parametric Mann–Whitney U test for skewed variables.
Although the overall study sample size was substantial, the
statistical power for testing the effect of covariates on each
disease was limited due to the number of children having
had that diagnosis. The TRIGR study had >80% power to
detect HRs of 0.5 or less in autoantibody incidence according
to the use of hydrolysed formula. The power to detect differ-
ences in the incidence of atopic diseases, which occurred with
lower frequency, conditioned upon autoantibody occurrence
was much less. The detectable HRs at 80% power ranged from
0.1 to 0.3 for asthma, allergic rhinitis and eczema.
Data were analysed using the Statistical Analysis System
software (version 9.4; SAS Institute, Cary, NC, USA). Two-
tailed p values less than 0.05 were considered to be statistical-
ly significant. No adjustment in type 1 error was made for
multiple comparisons except in the context of the multiple
Cox regression model.
The TRIGR study and this ancillary study was approved by
local institutional review or ethics boards and was monitored
by an External Evaluation Committee formed by the National
Institutes of Health.
Results
Of the total study population, 1106 (51.2%) completed the
ISAAC questionnaire and were included in this analysis.
Altogether, 268 children in this asthma and allergy study
population were exclusively breastfed at 3 months of age,
451 received hydrolysed formula, 350 received cow’s milk
formula and the remaining 37 were not exclusively breastfed
but did not receive either of the formulas. There were statisti-
cally significant differences between the enrolled total TRIGR
cohort and those who completed the ISAAC questionnaire
according to their demographic characteristics. A higher
proportion of the ISAAC responders were enrolled from
TRIGR European countries as compared with North
America or Australia (62% vs 43%, p < 0.01), had an
increased number of foods introduced by 6 months of age
(20% vs 13%, p < 0.01) (notably potatoes/vegetables [72%
vs 64%] and fruits/fruit juices [69% vs 62%]) and were exclu-
sively breastfed for the first 3 months of life (24% vs 18%,
p < 0.01). With regard to other demographics measured, there
were no statistically significant differences between those who
responded to the ISAAC questionnaire and those who did not.
Comparing feeding practices during the first 3 months of
life for those who completed the ISAAC questionnaire,
among those exclusively breastfed or that did not receive
hydrolysed or cow’s milk-containing formulas, a higher
percentage of respondents were from sites in Europe as
compared with the remaining TRIGR sites (72.5% vs
58.3%, p < 0.001) or were delivered vaginally (71.1% vs
52.2%, p < 0.001), and a lower percentage had diets that
included potatoes/vegetables (62.6% vs 75.5%), fruits/fruit
juices (55.4% vs 73.5%) and cereals (55.4% vs 78.4%) by
6 months of age (all p < 0.0001). Also, respondents who were
exclusively breastfed or did not receive hydrolysed or cow’s
milk-containing formulas were less likely to come from fami-
lies where mothers smoked during pregnancy (3.0% vs 7.5%,
p = 0.005) or whose children lived in a household with an
active smoker during the first year of life (17.0% vs 23.3%,
p = 0.023), as compared with the other feeding groups
(Table 1).
The cumulative incidence rates for eczema, allergic rhinitis
and asthma were 22% (N = 251 [95% CI 18.5%, 25.7%]), 9%
(N = 112 [95% CI 6.8%, 11.2%]) and 7.5% (N = 89 [95% CI
3.8, 11.2]), respectively, by 9–11 years of age (Fig. 1). Among
those who remained autoantibody negative (N = 599), the
cumulative incidence rates of eczema, allergic rhinitis and
asthma were 33% (95% CI 29.3%, 36.9%), 14% (95% CI
10.8%, 17.8%) and 12.4% (95% CI 9.7%, 15.1%) by 9–
11 years of age. These rates are lower than anticipated from
the ISAAC study conducted in these same countries, but not
by much when considering those who remained autoantibody
negative through the follow-up period. Among the TRIGR
countries, the prevalence of asthma in children between 6
and 14 years of age as defined by the ISAAC study was
highest in Australia (26–37% for asthma). For the USA, the
prevalence was 17–20%, and in Canada it was 16–19%. The
prevalence was lowest among European countries
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participating in TRIGR, ranging from the lowest estimates in
Estonia (4–5%) to the highest in Italy (11–15%). The preva-
lence rates of current wheezing according to ISAAC in chil-
dren of 6–14 years old were: Australia 20–31%, USA 19–
22%, Canada 14–15%, Estonia 9–10% and Italy 8–11%.
The prevalence rates of allergic sensitisation to any allergen
across the TRIGR countries were in the range of 35–40%
[19–23].
Disease risk was significantly increased (p < 0.01) for each
of the three diseases with a family history of that disease. Also,
there was a significantly higher risk for asthma (HR 81.02,
p < 0.01) if eczema was diagnosed 6 months earlier or within
the first 6 months of age (HR 2.37, p = 0.002). Excluding IA-
2A and ZnT8A due to small numbers (N = 8 for each), the
development of islet cell autoimmunitywas significantly asso-
ciated with a reduced subsequent risk of asthma or eczema, no
matter which autoantibody was present, with HRs ranging
from 0.13 to 0.18 (Table 2, Fig. 2). The presence of ICA
(N = 233, HR 0.41, p < 0.01) significantly reduced the risk
of allergic rhinitis, but neither IAA (N = 39) nor GADA
(N = 48) had a significant impact on allergic rhinitis (HR
0.63, p = 0.14 and HR 0.57, p = 0.09, respectively). ICA, as
the first-appearing autoantibody (N = 233), significantly
reduced the subsequent risk of asthma (HR 0.22, p < 0.01),
rhinitis (HR 0.40, p < 0.01) and eczema (HR 0.27, p < 0.01).
IAA or GADA as the first-appearing autoantibody was
followed by a significant risk reduction only for eczema (HR
0.29, p = 0.01 and HR 0.33, p = 0.02, respectively). The only
other significant finding was the lower risk (HR 0.55, p =
0.01) of asthma for study children from Europe as compared
with children from the USA.
Multivariable analyses of these risk factors resulted in
consistent statistically significant reduced risk when ICA
was the first-appearing autoantibody (p < 0.01; HR 0.24, HR
0.40 and HR 0.27 for asthma, allergic rhinitis and eczema,
respectively). When multiple autoantibodies appeared first
(N = 169), the reduced risk remained significant for asthma
(HR 0.06, p < 0.01) and allergic rhinitis (HR 0.38, p < 0.01),
but the risk reduction was no longer significant for eczema
(p < 0.12). For eczema, IAA and GADA, as first-appearing
autoantibodies, were each associated with a statistically signif-
icant risk reduction (HR 0.30, p = 0.02 and HR 0.34, p = 0.02,
respectively). The appearance of these autoantibodies individ-
ually did not result in a statistically significant impact on risk
for asthma or allergic rhinitis. Family history (either one or
both parents) conveyed a significantly higher risk across all
three diagnoses, as did a family history of eczema for asthma,
similar to what was seen in the univariate analyses (Table 3).
Discussion
The lower reported incidence of persistent asthma, allergic
rhinitis and eczema in the TRIGR countries could be
explained, in part, by the higher incidence of diabetes-
related autoantibodies in the TRIGR study population and
the inverse relationship of their incidence found in this study.
This finding is consistent with other studies in North America
[24] and Europe [25] that report a lower prevalence of asthma
in children with type 1 diabetes, as compared with the general
population; however, some findings have differed, especially
the USA [26]. Hence, the relationship between type 1 diabetes
and atopic disease remains controversial. That the TRIGR
study cohort was not population based, but selectively includ-
ed children at higher genetic risk for diabetes among families
with a first-degree relative with type 1 diabetes, could be
considered a limitation on the findings reported herein.
However, this paper focuses on the relationship between
Fig. 1 Cumulative incidence of
persistent asthma, atopic eczema
and allergic rhinitis
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autoimmunity and asthma, allergic rhinitis and eczema, not the
prevalence of these disorders. The selection bias would be perti-
nent only if one thought that the relationshipwas different among
those who developed diabetes-related autoimmunity and these
atopic diseases in other, lower risk, HLA groups. There are no
reports in the literature to support this contention.
The occurrence of diabetes-related autoantibodies showed a
protective association with subsequent development of persistent
asthma and atopic eczema. The incidence of allergic rhinitis was
not significantly related to the occurrence of IAA or GADA
(statistical power was limited), but demonstrated the same inverse
relationship, as did the other diseases, with ICA or when multiple
autoantibodies first appeared together. Hence, when considering
putative confounders and all of the first-appearing endpoints
simultaneously, ICA and multiple autoantibodies were associated
with persistent asthma and allergic rhinitis, and ICA, IAA and
GADA with atopic eczema. The lack of statistical significance in
the comparison of effect of the occurrence of IAA or GADAwith
allergic rhinitis must be interpretedwith some caution as the study
has limited statistical power, as noted above.
These findings extend the observation of an inverse relation-
ship between type 1 diabetes and later development of asthma,
showing the same directional effect but suggesting that the protec-
tive effect extends to the first appearance of autoantibodies [27].
As far as we are aware, this has not been shown before. An earlier
study has observed a direct association between wheezing during
the first year of life and presence of GADA and IA-2A autoim-
munity at the age of 2.5 years [28]. The present study did not
observe sufficient numbers of cases of seroconversion to autoan-
tibody positivity after a diagnosis of asthma or allergic rhinitis to
test the question of whether earlier diagnosis of these diseases
increased the incidence of autoimmunity. In this population, auto-
antibodies most often occurred in early childhood, preceding
disease diagnosis, except for eczema, which was diagnosed at a
very early age. In this study, islet autoantibodies were rarely seen
before 1 year of age. In other studies [8], when they are seen, IAA
is most often the first-appearing autoantibody. Also, this study
did not observe a difference in disease diagnosis according to
the sex of the child. The random allocation to different early
feeding patterns also supports the lack of an observed
Fig. 2 Cumulative incidence by prior autoantibody status for asthma (a), eczema (b) and allergic rhinitis (c)
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relationship between atopic disease incidence and early
exposure to hydrolysed formula compared with cow’s
milk-based formula. Despite the inclusion of a series of
potential exposures that could be related to disease inci-
dence, only family history and the prior development of
diabetes-related autoimmunity were significant.
The findings of the present study add evidence to the relation-
ships between atopic diseases and diabetes-related autoimmunity,
and also suggest that the interaction depends upon which autoan-
tibody appeared first for eczema but not for asthma or rhinitis.
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